Treatment of osteomyelitis in rats by injection of degradable polymer releasing gentamicin.
We evaluated the potential of an injectable degradable polymer-poly(sebacic-co-ricinoleic-ester-anhydride) containing gentamicin for the treatment of osteomyelitis. Osteomyelitis of both tibiae was induced in 13 female Fischer rats by injecting a suspension containing approximately 105 (CFU)/ml of S. aureus into the tibial medullar canal. Three weeks later both tibiae were X-rayed, drilled down the medullar canal, washed with 50 microl gentamicin solution (80 mg/2 ml) and then injected with 50 microl P(SA-RA)+gentamycin 20% w/v to the right tibia and 50 microl P(SA-RA) without gentamicin to the left tibia. After an additional 3 weeks, the rats were sacrificed, and radiographs of the tibiae were taken. Histopathological evaluation of the tibiae was done in a blinded manner. X-ray radiographs showed that all tibiae developed changes compatible with osteomyelitis in 3 weeks. Histological evaluation revealed significant differences between right and left tibiae in 10 rats. In the left tibia moderate intramedullary abscess formation occurred. In most treated tibiae typical changes included the absence (or minimal grade only) of abscesses. The treated group developed significantly less intramedullary abscesses; the p value was 0.028. Locally injected degradable polymer releasing gentamicin proved to be efficient histologically in the treatment of osteomyelitis.
Brin
Yaron S
YS
Department of Orthopaedic Surgery, Meir Medical Center, 48 Tchernichovsky Str., Kfar-Saba 44281, Israel. yaronbrin@gmail.com
Golenser
Jacob
J
Mizrahi
Boaz
B
Maoz
Guy
G
Domb
Abraham J
AJ
Peddada
Shyamal
S
Tuvia
Shmuel
S
Nyska
Abraham
A
Nyska
Meir
M
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001672:Biocompatible Materials / Q000737:chemistry*; D003652:Decanoic Acids / Q000737:chemistry*; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015552:Injections, Intralesional; D010019:Osteomyelitis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D011108:Polymers / Q000737:chemistry*; D011859:Radiography; D051381:Rats; D011916:Rats, Inbred F344; D012277:Ricinoleic Acids / Q000737:chemistry*; D012995:Solubility; D013203:Staphylococcal Infections / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D013977:Tibia / Q000000981:diagnostic imaging / Q000382:microbiology / Q000473:pathology
D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D003652:Decanoic Acids; D004337:Drug Carriers; D005839:Gentamicins; C493322:Poly(sebacic acid-co-ricinoleic acid); D011108:Polymers; D012277:Ricinoleic Acids